Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis

(2018) Karl L Insogna et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Outcome of adult patients with X-linked hypophosphatemia caused by PHEX gene mutations

(2018) Douglas Chesher et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology

(2015) Sue Richards et al.   GENETICS IN MEDICINE

Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23

(2015) Erik A. Imel et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia

(2014) Thomas O. Carpenter et al.   JOURNAL OF CLINICAL INVESTIGATION

Therapeutic management of hypophosphatemic rickets from infancy to adulthood

(2014) Agnès Linglart et al.   Endocrine Connections

A New Equation to Estimate Glomerular Filtration Rate

(2013) Andrew S. Levey et al.   ANNALS OF INTERNAL MEDICINE

A clinician's guide to X-linked hypophosphatemia

(2011) Thomas O Carpenter et al.   JOURNAL OF BONE AND MINERAL RESEARCH